An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Clinical trial NCT03227432 · WITHDRAWN
Trial details
- NCT number
- NCT03227432
- Sponsor
- Dana-Farber Cancer Institute
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-01
- Primary completion
- 2021-12-31
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.